Skip to content

Kaypok selects Zync to power its global “big data” technology brand

Spin-off company based on founder Razieh Niazi’s research at York University

TORONTO, Dec. 6, 2012 — Kaypok Inc., a start-up company whose technology delivers insight into unstructured big data, today announced that it has selected Zync as its agency of record to create and launch Kaypok’s brand globally.

Kaypok Inc., which was spun off from York University research with support and funding from MaRS Innovation, filters, categorizes, identifies meaning and measures the root cause and emotions buried within unstructured text to understand what people are saying and feeling. Kaypok Inc. launched nationally at the iStrategy Digital Marketing Conference in Toronto on December 4, 2012.

Continue Reading

VitalHub’s Chart Makes Apple’s Top 80 List of Doctor Apps

VitalHub Corp Logo: Patient information made easyVitalHub Chart has been named to Apple’s list of top 80 apps for doctors, nurses, patients and healthcare professionals in the “EMR and patient monitoring” category.

Here’s a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators:

VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts on rounds.”

Continue Reading

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:

One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.

“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.

Continue Reading
Back To Top